This national clinical trial aims to identify treatments that may be beneficial for people hospitalised with suspected or confirmed COVID-19 A range of potential treatments have been suggested for COVID-19 but nobody knows if any of them will turn out to be more effective in helping people recover than the usual standard of hospital care which all patients will receive. The RECOVERY Trial is currently testing some of these suggested treatments: Low-dose Dexamethasone (now only recruiting children) Azithromycin (a commonly used antibiotic) Tocilizumab (an anti-inflammatory treatment given by injection) Convalescent plasma (collected from donors who have recovered from COVID-19 and contains antibodies against the SARS-CoV-2 virus) REGN-COV2 (a combination of monoclonal antibodies directed against coronavirus) Aspirin (commonly used to thin the blood). Data from the trial are regularly reviewed so that any effective treatment can be identified quickly and made available to all patients. Please see our news page for results that RECOVERY has already found. The RECOVERY Trial team will constantly review information on new drugs and include promising ones in the trial.
